Myeloid dysregulation and therapeutic intervention in COVID-19

• Published in: Seminars in immunology Vol. 55; p. 101524
• Main Authors: Gu, Runxia, Mao, Tianyang, Lu, Qiao, Tianjiao Su, Tina, Wang, Jun
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2021
• Subjects: COVID-19; COVID-19 Drug Treatment; Humans; Hyperactivation; Immunity, Innate; Immunopathology; Immunotherapy; Myeloid cell; Myeloid Cells; Pathogenesis; Review; SARS-CoV-2; COVID-19; Immunopathology; SARS-CoV-2; Pathogenesis; Immunotherapy; Hyperactivation; Myeloid cell
• ISSN: 1044-5323; 1096-3618; 1096-3618
• DOI: 10.1016/j.smim.2021.101524

•Myeloid cell hyperactivation is a key mechanism of COVID-19 pathogenesis.•Dysregulation occurs via direct innate sensing or stimulation of myeloid receptors by viral components.•Potential COVID-19 therapies should focus on correcting myeloid dysregulation, particularly at late stages of the disease. The dysregulation of myeloid cell responses is increasingly demonstrated to be a major mechanism of pathogenesis for COVID-19. The pathological cellular and cytokine signatures associated with this disease point to a critical role of a hyperactivated innate immune response in driving pathology. Unique immunopathological features of COVID-19 include myeloid-cell dominant inflammation and cytokine release syndrome (CRS) alongside lymphopenia and acute respiratory distress syndrome (ARDS), all of which correlate with severe disease. Studies suggest a range of causes mediating myeloid hyperactivation, such as aberrant innate sensing, asynchronized immune cellular responses, as well as direct viral protein/host interactions. These include the recent identification of new myeloid cell receptors that bind SARS-CoV-2, which drive myeloid cell hyperinflammatory responses independently of lung epithelial cell infection via the canonical receptor, angiotensin-converting enzyme 2 (ACE2). The spectrum and nature of myeloid cell dysregulation in COVID-19 also differs from, at least to some extent, what is observed in other infectious diseases involving myeloid cell activation. While much of the therapeutic effort has focused on preventative measures with vaccines or neutralizing antibodies that block viral infection, recent clinical trials have also targeted myeloid cells and the associated cytokines as a means to resolve CRS and severe disease, with promising but thus far modest effects. In this review, we critically examine potential mechanisms driving myeloid cell dysregulation, leading to immunopathology and severe disease, and discuss potential therapeutic strategies targeting myeloid cells as a new paradigm for COVID-19 treatment.